2,700
+3.05%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Falco Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 4671.T. It has been listed since 1 April 1997. In the fiscal year to 31 March 2026, it reported revenue of ¥43.58bn and net income of ¥2.02bn. At that date it held total assets of ¥36.86bn and shareholders' equity of ¥25.87bn.
FALCO HOLDINGS Co., Ltd. engages in the provision of clinical testing and dispensing pharmacy services. The company is headquartered in Osaka, Osaka-Fu. The firm operates in two business segments. The Clinical Testing segment is engaged in the contracted clinical specimen testing business for hospitals and clinics, as well as the development and sale of electronic medical charts and other medical information systems, and the wholesale of in-vitro diagnostic drugs. The Dispensing Pharmacy segment is engaged in the operation of dispensing pharmacies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 1 Apr 1997
- Employees
- 1,159
- Website
- falco-hd.co.jp ↗
Leadership
Pay as last reported
- Mr. Tadashi YasudaPresident, Executive president, Representative Director, since 2003
- Mr. Nobumasa MatsubaraExecutive Vice President, Representative Director, since 2014
- Mr. Yoichi KawataManaging Director, Manager of linical Business Office, President of Subsidiary, since 2018
- Mr. Takafumi FukuiSenior Managing Executive Officer, Manager of Genome Business, Director, since 2022
- Mr. Hisayuki OhmaExecutive Officer, Assistant Manager of Pharmaceutical Business
- Mr. Osamu AbeExecutive Officer, Manager of Pharmaceutical Business Office
- Mr. Shuhei KurodaExecutive Officer, Manager of Administration Office, Assistant Manager of ICT Business Office, Assistant Manager of Genome Business
- Mr. Tetsuo GodaManager of Business Planning Office, Director, since 2019
- Mr. Masahiro IdaDirector
- Mr. Takehiro KatsuyamaIndependent Director
- Ms. Keiko KousakaIndependent Director
- Ms. Kinya NaitoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Osaka, Osaka-Fu with 1,159 employees.
- Operates in two business segments: Clinical Testing and Dispensing Pharmacy.
- Provides clinical testing, dispensing pharmacy services, and medical information systems.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No financial data or performance metrics provided.
- No details on market share or competitive position.
Opportunities
- Expansion in clinical testing services for hospitals and clinics.
- Growth potential in electronic medical charts and medical information systems.
- Potential for increased wholesale of in-vitro diagnostic drugs.
Threats
- Dependence on hospital and clinic contracts for clinical testing segment.
- Regulatory changes in health care industry could impact operations.
- Competition in dispensing pharmacy segment may affect profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.